A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

Wolfgang Wick, Harald Fricke, Klaus Junge, Grigory Kobyakov, Tobias Martens, Oliver Heese, Benedikt Wiestler, Maximilian G. Schliesser, Andreas von Deimling, Josef Pichler, E R Vetlova, Inga Harting, Jürgen Debus, Christian Hartmann, Claudia Kunz, Michael Platten, Martin Bendszus, Stephanie E. CombsClinical 2014 · DOI

Abstract

CD95 pathway inhibition in combination with rRT is an innovative concept with clinical efficacy. It warrants further clinical development. CD95L promoter methylation in the tumor may be developed as a biomarker.
BibTeX
@inproceedings{wick2014phase,
  author = {Wolfgang Wick and Harald Fricke and Klaus Junge and Grigory Kobyakov and Tobias Martens and Oliver Heese and Benedikt Wiestler and Maximilian G. Schliesser and Andreas von Deimling and Josef Pichler and E R Vetlova and Inga Harting and Jürgen Debus and Christian Hartmann and Claudia Kunz and Michael Platten and Martin Bendszus and Stephanie E. Combs},
  title = {{A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma}},
  booktitle = {Clinical},
  year = {2014},
  doi = {10.1158/1078-0432.ccr-14-0951-t},
}

Loading related content...

Figure